ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Qi, Mengfan, Tian, Ye, Li, Wang, Li, Dan, Zhao, Tian, Yang, Yuxin, Li, Qiwen, Chen, Sujun, Yang, Yan, Zhang, Zhixiong, Tang, Liang, Liu, Zhonghua, Su, Bo, Li, Fei, Feng, Yonghong, Fei, Ke, Zhang, Peng, Zhang, Fan, Zhang, Lei
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2018
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844726/
https://ncbi.nlm.nih.gov/pubmed/29552290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24147
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker